FDA: Doctors should use genetic test before prescribing abacavir

07/24/2008 | NYTimes.com

The FDA is expected to release an advisory today that calls on doctors to use a genetic test before prescribing abacavir -- sold by GlaxoSmithKline under the name Ziagen -- to prevent severe allergic reactions in patients carrying an immune-system gene variant. The recommendation will be included in a "black box" warning on Ziagen's new label, which will also mention the increased risk of heart attack based on "inconclusive" study data.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY